The medication showed promise as correction and maintenance therapy in a phase 2b trial of non-dialysis CKD patients with anemia.
Study finds no decrease in the risk for mortality, myocardial infarction, or heart failure in the first 180 days.
Investigators found a U-shaped curve of mortality against ferritin/TSAT levels in patients without autosomal dominant polycystic kidney disease, but not in those with the disease.
Using statins for more than 3 months was significantly associated with 85% lower odds of ESA hyporesponsiveness in CKD patients.
Respondents to an online poll were more likely to search for anemia information online rather than ask their nephrologists.
People nationwide, especially those with type O blood, are urged to donate as soon as possible
Agency cannot accept new fees or applications until the shutdown is over
The global Phase 3 program consists of more than 9000 patients.
The investigational drug appeared safe and effective in 3 phase 2b trials.
In a Japanese study, targeting high hemoglobin concentrations of 12.5-13.5 g/dL with erythropoiesis-stimulating agents resulted in longer graft survival.